Cargando…

Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers

BACKGROUND: A higher risk for breast and ovarian cancer has been reported in BRCA carriers and prophylactic surgeries are proposed to reduce this risk. This retrospective cohort study has evaluated the indication of BRCA1/2 genetic tests in Iranian women and the rate of women's acceptance of pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasigh, Mahtab, Eslami, Bita, Elahi, Ahmad, Kaviani, Ahmad, Shirkoohi, Reza, Majidzadeh, Keivan, Nazarian, Newsha, Omranipour, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830810/
https://www.ncbi.nlm.nih.gov/pubmed/35023322
http://dx.doi.org/10.1002/mgg3.1867
_version_ 1784648356206739456
author Vasigh, Mahtab
Eslami, Bita
Elahi, Ahmad
Kaviani, Ahmad
Shirkoohi, Reza
Majidzadeh, Keivan
Nazarian, Newsha
Omranipour, Ramesh
author_facet Vasigh, Mahtab
Eslami, Bita
Elahi, Ahmad
Kaviani, Ahmad
Shirkoohi, Reza
Majidzadeh, Keivan
Nazarian, Newsha
Omranipour, Ramesh
author_sort Vasigh, Mahtab
collection PubMed
description BACKGROUND: A higher risk for breast and ovarian cancer has been reported in BRCA carriers and prophylactic surgeries are proposed to reduce this risk. This retrospective cohort study has evaluated the indication of BRCA1/2 genetic tests in Iranian women and the rate of women's acceptance of prophylactic surgeries recommended by the surgeon. METHODS: Medical records of 147 high‐risk women according to NCCN clinical practice guidelines who referred for BRCA mutations testing were assessed. Individual information, indications for BRCA1/2 genetic testing and their results, physician recommendations, and type of accepted surgery were registered. To evaluate the current status of women an active visit follow‐up every six months was conducted. RESULTS: The mean age of women was 43.40 ± 10.94 and the median follow‐up time was 1.92 years. Genetic test results showed 49(33.3%) women were positive for either BRCA1/2 mutations. Although the occurrence of breast cancer younger than 40 was the most common indication for genetic tests (26.5%), positive breast cancer history in first‐degree relatives and two relatives younger than 50 was the most common indications with positive results. The rate of acceptance of prophylactic mastectomy and bilateral salpingo‐oophorectomy was (14.3% and 34.7%) in BRCA mutation carriers. CONCLUSION: If the onset of breast cancer at a young age (less than 40) will be the only indication for a BRCA analysis, the rate of a positive result (12.8%) is very low. Further studies are warranted to evaluate the age limit for genetic testing in our country. Prophylactic mastectomy acceptance is very low in BRCA1/2 carriers in our centers.
format Online
Article
Text
id pubmed-8830810
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88308102022-02-14 Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers Vasigh, Mahtab Eslami, Bita Elahi, Ahmad Kaviani, Ahmad Shirkoohi, Reza Majidzadeh, Keivan Nazarian, Newsha Omranipour, Ramesh Mol Genet Genomic Med Original Articles BACKGROUND: A higher risk for breast and ovarian cancer has been reported in BRCA carriers and prophylactic surgeries are proposed to reduce this risk. This retrospective cohort study has evaluated the indication of BRCA1/2 genetic tests in Iranian women and the rate of women's acceptance of prophylactic surgeries recommended by the surgeon. METHODS: Medical records of 147 high‐risk women according to NCCN clinical practice guidelines who referred for BRCA mutations testing were assessed. Individual information, indications for BRCA1/2 genetic testing and their results, physician recommendations, and type of accepted surgery were registered. To evaluate the current status of women an active visit follow‐up every six months was conducted. RESULTS: The mean age of women was 43.40 ± 10.94 and the median follow‐up time was 1.92 years. Genetic test results showed 49(33.3%) women were positive for either BRCA1/2 mutations. Although the occurrence of breast cancer younger than 40 was the most common indication for genetic tests (26.5%), positive breast cancer history in first‐degree relatives and two relatives younger than 50 was the most common indications with positive results. The rate of acceptance of prophylactic mastectomy and bilateral salpingo‐oophorectomy was (14.3% and 34.7%) in BRCA mutation carriers. CONCLUSION: If the onset of breast cancer at a young age (less than 40) will be the only indication for a BRCA analysis, the rate of a positive result (12.8%) is very low. Further studies are warranted to evaluate the age limit for genetic testing in our country. Prophylactic mastectomy acceptance is very low in BRCA1/2 carriers in our centers. John Wiley and Sons Inc. 2022-01-12 /pmc/articles/PMC8830810/ /pubmed/35023322 http://dx.doi.org/10.1002/mgg3.1867 Text en © 2022 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Vasigh, Mahtab
Eslami, Bita
Elahi, Ahmad
Kaviani, Ahmad
Shirkoohi, Reza
Majidzadeh, Keivan
Nazarian, Newsha
Omranipour, Ramesh
Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers
title Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers
title_full Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers
title_fullStr Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers
title_full_unstemmed Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers
title_short Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk‐reducing surgeries in BRCA mutation carriers
title_sort evaluation of the indication of brca1/2 genetic tests in iranian women and acceptance rate of risk‐reducing surgeries in brca mutation carriers
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830810/
https://www.ncbi.nlm.nih.gov/pubmed/35023322
http://dx.doi.org/10.1002/mgg3.1867
work_keys_str_mv AT vasighmahtab evaluationoftheindicationofbrca12genetictestsiniranianwomenandacceptancerateofriskreducingsurgeriesinbrcamutationcarriers
AT eslamibita evaluationoftheindicationofbrca12genetictestsiniranianwomenandacceptancerateofriskreducingsurgeriesinbrcamutationcarriers
AT elahiahmad evaluationoftheindicationofbrca12genetictestsiniranianwomenandacceptancerateofriskreducingsurgeriesinbrcamutationcarriers
AT kavianiahmad evaluationoftheindicationofbrca12genetictestsiniranianwomenandacceptancerateofriskreducingsurgeriesinbrcamutationcarriers
AT shirkoohireza evaluationoftheindicationofbrca12genetictestsiniranianwomenandacceptancerateofriskreducingsurgeriesinbrcamutationcarriers
AT majidzadehkeivan evaluationoftheindicationofbrca12genetictestsiniranianwomenandacceptancerateofriskreducingsurgeriesinbrcamutationcarriers
AT nazariannewsha evaluationoftheindicationofbrca12genetictestsiniranianwomenandacceptancerateofriskreducingsurgeriesinbrcamutationcarriers
AT omranipourramesh evaluationoftheindicationofbrca12genetictestsiniranianwomenandacceptancerateofriskreducingsurgeriesinbrcamutationcarriers